Cargando…
No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
The theoretical basis for use of histamine 2 (H(2))-receptor inhibitors to prevent hypersensitivity reactions for paclitaxel infusions is weak. This Editorial discusses a clinical study showing that ranitidine is not indicated any more in this setting and puts this in the context of other valuable e...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987749/ https://www.ncbi.nlm.nih.gov/pubmed/33762719 http://dx.doi.org/10.1038/s41416-021-01316-x |